ABEC launches 6,000L single-use bioreactor to answer scalability needs

By Vassia Barba

- Last updated on GMT

(Image: Getty/ArtRachen01)
(Image: Getty/ArtRachen01)

Related tags ABEC bioreactor

After breaking the 2,000L ‘ceiling’ of manufacturing capacity, ABEC launches a single-use bioreactor of 6,000L to answer clients’ scalability demands.

ABEC, a biopharmaceutical manufacturing services provider headquartered in Pennsylvania, US, announced the availability of Custom Single Run (CSR) bioreactors that possess working volumes up to 6,000L.

With the launch of CSR bioreactors, the company surpasses the threshold it reached in 2017​, when it designed and commercialized a bioreactor with 4,900L total production volume capabilities.

According to the company, the increased cell culture capacity per unit of floor space enabled with CSR can result in savings of capital, facility space, and disposables cost.

Made by stainless steel, CSR bioreactor has the potential to deliver equivalent power per volume while maintaining low shear mixing, ABEC states.

Additionally, the product retains the “material, instrument, and component supply chains remain fully-transparent and non-proprietary so that biopharmaceutical manufacturers have better control and flexibility to manage quality, cost, and regulatory compliance.”

Scott Pickering, the company’s CEO, commented that its customers require increased scalability while “realizing other single-use benefits, such as multi-product flexibility.”

Flexible’ cell culture platform

Concurrently with the launch of CSR bioreactor, the company introduced a cell platform for flexible, high-volume biopharmaceutical production, based on the existing CSR services for biopharmaceutical manufacturing.

The platform includes ABEC's CSR single-use bioreactors with production volumes up to 4,000L, CSR general mix systems with production volumes up to 5,000L, and solutions hold systems with production volumes up to 4,000L.

According to ABEC, adopting the platform may “enable flexible facilities to produce twice the product output from bioreactor to bulk fill,” ​while utilizing floor space comparable to current 2,000L-based facilities.

Additionally, the platform CSR products have the potential to improve operational efficiency by elevating buffer above the points of use, rather than current methods involving pushing totes or in-line conditioning.

Related news

Show more

Related products

Process optimization for mAb commercial manufacturing

Process optimization for mAb commercial manufacturing

Content provided by Catalent | 01-Jun-2023 | Product Presentation

Process characterization and validation is an important step in the product development journey and late-phase development, and it is required before transferring...